Gene: VTCN1

79679
B7-H4|B7H4|B7S1|B7X|B7h.5|PRO1291|VCTN1
V-set domain containing T cell activation inhibitor 1
protein-coding
1p13.1-p12
Ensembl:ENSG00000134258 MIM:608162 Vega:OTTHUMG00000012118 UniprotKB:Q7Z7D3
NC_000001.11
SNP Mapped
3   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
6.628e-1 (AD)  5.369e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs12098035chr1:117216829 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs1892409chr1:117216703 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)
rs3806373chr1:117211437 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
AMTN0.448
TRHR0.44
MPL0.411
C11orf400.407
KAZALD10.395
ST8SIA20.388
HCRTR10.383
CDRT15L20.376
FAM83F0.375
GRPR0.375

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GFRA1-0.329
LRRC1-0.309
AZGP1-0.304
KIF19-0.294
C2orf88-0.291
MYOT-0.271
IP6K3-0.267
FKBP5-0.265
NDE1-0.264
DOCK5-0.263

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C49562614-deoxy-11,12-didehydroandrographolide"14-deoxy-11,12-didehydroandrographolide results in decreased expression of VTCN1 mRNA"22101062
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of VTCN1 mRNA28959563
D004958Estradiol[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of VTCN1 mRNA19619570
D004958EstradiolEstradiol results in increased expression of VTCN1 mRNA19619570
C006780bisphenol Abisphenol A affects the expression of VTCN1 mRNA20170705
C006780bisphenol Abisphenol A results in decreased expression of VTCN1 mRNA25181051
D019256Cadmium ChlorideCadmium Chloride results in increased expression of VTCN1 mRNA25596134
C004656chloroacetaldehydechloroacetaldehyde affects the expression of VTCN1 mRNA25596134
C059262cidofovircidofovir results in increased expression of VTCN1 mRNA25596134
D004002Clodronic AcidClodronic Acid results in increased expression of VTCN1 mRNA25596134
D016572CyclosporineCyclosporine results in decreased expression of VTCN1 mRNA25596134|2798913
D016572CyclosporineCyclosporine results in decreased expression of VTCN1 mRNA25596134
D003999Dichloroacetic AcidDichloroacetic Acid results in increased expression of VTCN1 mRNA28962523
D002117CalcitriolCalcitriol results in increased expression of VTCN1 mRNA26485663
D004964EstriolEstriol results in increased expression of VTCN1 protein21317386
D004997Ethinyl EstradiolEthinyl Estradiol affects the expression of VTCN1 mRNA20170705
C039281furanfuran results in increased expression of VTCN1 mRNA27387713
D008727MethotrexateMethotrexate results in increased expression of VTCN1 mRNA24449571
D009532NickelNickel results in decreased expression of VTCN1 mRNA24768652|2558310
D010100OxygenOxygen deficiency affects the expression of VTCN1 mRNA25596134
D052638Particulate Matter[VTCN1 gene mutant form affects the susceptibility to Particulate Matter] which results in increased expression of VTCN1 mRNA21222557|2122255
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of VTCN1 mRNA"25510870
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in increased expression of VTCN1 mRNA26272509
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of VTCN1 mRNA19710929
D011285Pregnenolone CarbonitrilePregnenolone Carbonitrile results in increased expression of VTCN1 mRNA19162173
D011374ProgesteroneProgesterone results in decreased expression of VTCN1 mRNA21540246
C005556propionaldehydepropionaldehyde results in increased expression of VTCN1 mRNA26079696
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of VTCN1 mRNA25895662
D012834SilverSilver results in decreased expression of VTCN1 mRNA28959546
D013749Tetrachlorodibenzodioxin[Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of VTCN1 mRNA19619570
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of VTCN1 mRNA19619570|2290382
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of VTCN1 mRNA26377647
D014212TretinoinTretinoin results in increased expression of VTCN1 mRNA16249480|2193413
C012589trichostatin Atrichostatin A results in increased expression of VTCN1 mRNA24935251
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VTCN1 mRNA"27188386
D014635Valproic AcidValproic Acid results in increased expression of VTCN1 mRNA23179753|2438349
D014635Valproic AcidValproic Acid affects the expression of VTCN1 mRNA17963808
D001335Vehicle Emissions[VTCN1 gene mutant form affects the susceptibility to Vehicle Emissions] which results in increased expression of VTCN1 mRNA21222557|2122255
C088658zoledronic acidzoledronic acid results in increased expression of VTCN1 mRNA24714768|2559613

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003674molecular_function-ND-  
GO:0005102signaling receptor binding-IBA21873635  
GO:0005102signaling receptor binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0001562response to protozoan-IEA-  
GO:0001817regulation of cytokine production-IBA21873635  
GO:0002250adaptive immune response-IEA-  
GO:0042102positive regulation of T cell proliferation-IEA-  
GO:0042130negative regulation of T cell proliferation-IMP16606666  
GO:0043066negative regulation of apoptotic process-IMP15878339  
GO:0050776regulation of immune response-IBA21873635  
GO:0050852T cell receptor signaling pathway-IBA21873635  
GO:0050868negative regulation of T cell activation-IMP16606666  
GO:0072602interleukin-4 secretion-IEA-  
GO:0072643interferon-gamma secretion-IEA-  
GO:1900042positive regulation of interleukin-2 secretion-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0009897external side of plasma membrane-IBA21873635  
GO:0009897external side of plasma membrane-IDA16606666  
GO:0016021integral component of membrane-IEA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal